- Home
- PCRX vs CRMD Comparison
PCRX vs CRMD Comparison
Compare PCRX & CRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCRX
- CRMD
- Stock Information
- Founded
- PCRX 2006
- CRMD 2006
- Country
- PCRX United States
- CRMD United States
- Employees
- PCRX N/A
- CRMD N/A
- Industry
- PCRX Biotechnology: Pharmaceutical Preparations
- CRMD Biotechnology: Pharmaceutical Preparations
- Sector
- PCRX Health Care
- CRMD Health Care
- Exchange
- PCRX Nasdaq
- CRMD Nasdaq
- Market Cap
- PCRX 1.2B
- CRMD 973.3M
- IPO Year
- PCRX 2011
- CRMD 2010
- Fundamental
- Price
- PCRX $23.31
- CRMD $11.35
- Analyst Decision
- PCRX Buy
- CRMD Strong Buy
- Analyst Count
- PCRX 8
- CRMD 7
- Target Price
- PCRX $28.38
- CRMD $17.33
- AVG Volume (30 Days)
- PCRX 537.5K
- CRMD 2.4M
- Earning Date
- PCRX 07-29-2025
- CRMD 08-13-2025
- Dividend Yield
- PCRX N/A
- CRMD N/A
- EPS Growth
- PCRX N/A
- CRMD N/A
- EPS
- PCRX N/A
- CRMD 0.28
- Revenue
- PCRX $702,772,000.00
- CRMD $82,553,827.00
- Revenue This Year
- PCRX $7.54
- CRMD $238.38
- Revenue Next Year
- PCRX $10.78
- CRMD $53.52
- P/E Ratio
- PCRX N/A
- CRMD $40.64
- Revenue Growth
- PCRX 3.08
- CRMD N/A
- 52 Week Low
- PCRX $11.16
- CRMD $3.61
- 52 Week High
- PCRX $27.64
- CRMD $17.43
- Technical
- Relative Strength Index (RSI)
- PCRX 37.20
- CRMD 38.32
- Support Level
- PCRX $22.82
- CRMD $11.21
- Resistance Level
- PCRX $23.83
- CRMD $11.74
- Average True Range (ATR)
- PCRX 0.67
- CRMD 0.64
- MACD
- PCRX -0.05
- CRMD -0.45
- Stochastic Oscillator
- PCRX 20.73
- CRMD 2.25
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
About CRMD CorMedix Inc.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.